These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30984563)

  • 1. Reducing oxidative toxicity of L-dopa in combination with two different antioxidants: an essential oil isolated from Rosa Damascena Mill., and vitamin C.
    Nikolova G; Karamalakova Y; Gadjeva V
    Toxicol Rep; 2019; 6():267-271. PubMed ID: 30984563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effect of two essential oils isolated from Rosa damascena Mill. and Lavandula angustifolia Mill, and two classic antioxidants against L-dopa oxidative toxicity induced in healthy mice.
    Nikolova G; Karamalakova Y; Kovacheva N; Stanev S; Zheleva A; Gadjeva V
    Regul Toxicol Pharmacol; 2016 Nov; 81():1-7. PubMed ID: 27381452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective Effect of Rosa damascena Against Aluminum Chloride-Induced Oxidative Stress.
    Zahedi-Amiri Z; Taravati A; Hejazian LB
    Biol Trace Elem Res; 2019 Jan; 187(1):120-127. PubMed ID: 29704206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multi-biomarker analysis of the antioxidant efficacy of Parkinson's disease therapy.
    Colamartino M; Duranti G; Ceci R; Sabatini S; Testa A; Cozzi R
    Toxicol In Vitro; 2018 Mar; 47():1-7. PubMed ID: 29080800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-parkinsonian mice.
    Zaitone SA; Hammad LN; Farag NE
    Pharmacol Rep; 2013; 65(5):1213-26. PubMed ID: 24399717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pergolide mesylate, a dopaminergic receptor agonist, applied with L-DOPA enhances serum antioxidant enzyme activity in Parkinson disease.
    Chalimoniuk M; Stepień A; Strosznajder JB
    Clin Neuropharmacol; 2004; 27(5):223-9. PubMed ID: 15602103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resveratrol synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson disease in mice.
    Liu Q; Zhu D; Jiang P; Tang X; Lang Q; Yu Q; Zhang S; Che Y; Feng X
    Behav Brain Res; 2019 Jul; 367():10-18. PubMed ID: 30922940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine- and L-beta-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors.
    Lai CT; Yu PH
    Biochem Pharmacol; 1997 Feb; 53(3):363-72. PubMed ID: 9065740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine.
    Pedrosa R; Soares-da-Silva P
    Br J Pharmacol; 2002 Dec; 137(8):1305-13. PubMed ID: 12466240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosa damascena Mill. Essential Oil Has Protective Effect Against Testicular Damage in Diabetic Rats.
    Hamedi S; Shomali T; Haghighat A
    J Diet Suppl; 2018 May; 15(3):311-317. PubMed ID: 28792252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-DOPA causes mitochondrial dysfunction in vitro: A novel mechanism of L-DOPA toxicity uncovered.
    Giannopoulos S; Samardzic K; Raymond BBA; Djordjevic SP; Rodgers KJ
    Int J Biochem Cell Biol; 2019 Dec; 117():105624. PubMed ID: 31654750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of topical Rose (Rosa damascena Mill.) oil for migraine headache: A randomized double-blinded placebo-controlled cross-over trial.
    Niazi M; Hashempur MH; Taghizadeh M; Heydari M; Shariat A
    Complement Ther Med; 2017 Oct; 34():35-41. PubMed ID: 28917373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carnosine Treatment Diminished Oxidative Stress and Glycation Products in Serum and Tissues of D-Galactose-Treated Rats.
    Aydin F; Kalaz EB; Kucukgergin C; Coban J; Dogru-Abbasoglu S; Uysal M
    Curr Aging Sci; 2018; 11(1):10-15. PubMed ID: 28676006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of oxidative stress induced by L-dopa on endogenous antioxidants in PC-12 cells.
    Vatassery GT; Smith WE; Quach HT
    Ann N Y Acad Sci; 2006 Aug; 1074():330-6. PubMed ID: 17105929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The medical treatment of Parkinson disease from James Parkinson to George Cotzias.
    Fahn S
    Mov Disord; 2015 Jan; 30(1):4-18. PubMed ID: 25491387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys.
    Lyras L; Zeng BY; McKenzie G; Pearce RK; Halliwell B; Jenner P
    J Neural Transm (Vienna); 2002; 109(1):53-67. PubMed ID: 11793162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid peroxidation in brain: interactions of L-DOPA/dopamine with ascorbate and iron.
    Li CL; Werner P; Cohen G
    Neurodegeneration; 1995 Jun; 4(2):147-53. PubMed ID: 7583678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases.
    Babizhayev MA; Kasus-Jacobi A
    Curr Clin Pharmacol; 2009 Jan; 4(1):4-37. PubMed ID: 19149498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.